1. Home
  2. Flashcards
  3. Preview

Antiemetic Regimens

  1. Carmustine >250mg/m^2
    High risk
  2. Cyclophosphamide >/= 1500m^2
    High risk
  3. Dacarbazine
    High risk
  4. Procarbazine
    High risk
  5. Cisplatin
    High risk
  6. Cyclophosphamide < 1500m^2 with anthracycline
    High risk
  7. Dactinomycin
    High risk
  8. Streptozocin
    High risk
  9. Aldesleukin >12 - 15 million units/m^2
    Moderate risk
  10. Amsacrine
    Moderate risk
  11. Arsenic Trioxide
    Moderate risk
  12. Azacitadine
    Moderate risk
  13. Busulfan > 4mg/day
    Moderate risk
  14. Carboplatin
    Moderate risk
  15. Carmustine </= 250mg/m^2
    Moderate risk
  16. Cyclophosphamide (oral)
    Moderate risk
  17. Cyclophosphamide < 1500mg/m^2 without anthracycline
    Moderate risk
  18. Cytarabine > 1000mg/m^2
    Moderate risk
  19. Daunorubicin
    Moderate risk
  20. Doxorubicin
    Moderate risk
  21. Epirubicin
    Moderate risk
  22. Fotemustine
    Moderate risk
  23. Idarubicin
    Moderate risk
  24. Ifosfamide
    Moderate risk
  25. Imatinib
    Moderate risk (however, daily use of antiemetics not recommended based on clinical experience)
  26. Irinotecan
    Moderate risk
  27. Lomustine
    Moderate risk
  28. Melphalan IV 50mg/m^2
    Moderate risk
  29. Methotrexate 250mg/m^2 to 1000mg/m^2
    Moderate risk
  30. Oxaliplatin
    Moderate risk
  31. Raltitrexed
    Moderate risk
  32. Temozolamide
    Moderate risk
  33. Vinorelbine
    Moderate risk
  34. Bortezomib
    Low risk (however, may have >10-30% emetogenic risk in clinical practice - consider treating as moderate risk)
  35. Capecitabine
    Low risk
  36. Cetuximab
    Low risk
  37. Cytarabine </= 1000mg/m^2
    Low risk
  38. Docetaxel
    Low risk
  39. Etoposide (IV and oral)
    Low risk
  40. Everolimus
    Low risk
  41. Methotrexate 50-250mg/m^2
    Low risk
  42. Mitomycin C
    Low risk
  43. Mitoxantrone
    Low risk
  44. Paclitaxel
    Low risk
  45. nab-Paclitaxel
    Low risk
  46. Panitumumab
    Low risk
  47. Pemetrexed
    Low risk
  48. Fludarabine (oral)
    Low risk
  49. Fluorouracil
    Low risk
  50. Gemcitabine
    Low risk
  51. Liposomal doxorubicin
    Low risk
  52. Sunitinib
    Low risk
  53. Temsirolimus
    Low risk
  54. Tenoposide
    Low risk
  55. Thiotepa
    Low risk
  56. Topotecan
    Low risk
  57. Alemtuzumab
    Minimal risk
  58. Aspariginase-Colaspase
    Minimal risk
  59. Bevacizumab
    Minimal risk
  60. Bleomycin
    Minimal risk
  61. Busulfan </= 4mg
    Minimal risk
  62. Chlorambucil
    Minimal risk
  63. Cladrabine
    Minimal risk
  64. Dasatinib
    Minimal risk
  65. Decitabine
    Minimal risk
  66. Erlotinib
    Minimal risk
  67. Fludarabine (IV)
    Minimal risk
  68. Gefitinib
    Minimal risk
  69. Gemtuzumab ozogamicin
    Minimal risk
  70. Hydroxurea
    Minimal risk
  71. Interferon alpha
    Minimal risk
  72. Lapatanib
    Minimal risk
  73. Lenalidomide
    Minimal risk
  74. Melphalan (oral)
    Minimal risk
  75. Mercaptopurine
    Minimal risk
  76. Methotrexate </= 50mg/m^2
    Minimal risk
  77. Methotrexate (oral)
    Minimal risk
  78. Rituximab
    Minimal risk
  79. Sorafenib
    Minimal risk
  80. Thalidomide
    Minimal risk
  81. Thioguanine
    Minimal risk
  82. Trastuzumab
    Minimal risk
  83. Vinblastine
    Minimal risk
  84. Vincristine
    Minimal risk
  85. Vinorelbine (IV)
    Minimal risk
Author
kvan4741
ID
157218
Card Set
Antiemetic Regimens
Description
Recommended antiemetic regimens for chemotheraphy of varying emetogenic risk
Updated

  1. Home
  2. Flashcards
  3. Preview